Developer docs
API playgroundTry for free, no card

Search company profiles

Exobiosphere

Full company profile

uuid0000yr5

Namestring
Exobiosphere
Legal namestring
Exobiosphere SARL
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Exobiosphere SARL is a Luxembourg-headquartered biotechnology company founded in 2024 that operates the world's first contract research organization (CRO) dedicated to high-throughput drug discovery in space. The company built and commercializes the Orbital High-Throughput Screener (OHTS), a carry-on suitcase-sized autonomous laboratory that integrates precision nanoliter liquid handling (via an integrated Formulatrix MANTIS dispenser), environmental control, robotic manipulation, and brightfield and fluorescent microscopy to run 2,000+ simultaneous biological experiments per microgravity mission. End-to-end mission services span assay adaptation, hardware qualification, launch integration, automated in-orbit experimentation with real-time data downlink, and post-mission data analysis for pharmaceutical, biotech, academic and government customers.

The business model is project- and mission-based with custom quotes; disclosed revenue streams include contract research services (per-mission CRO fees for pharma/biotech), space mission integration services (end-to-end orbital research as exemplified by the ESA contract), ground-based platform sales (terrestrial OHTS units sold to institutions such as the University of Notre Dame) and emerging data and analytics monetization tied to space-derived biological datasets. Go-to-market is direct enterprise sales augmented by channel partnerships with commercial space station operators (Vast, Voyager Technologies, Space Cargo Unlimited, ElevationSpace), government procurement (ESA, Luxembourg Space Agency, LuxIMPULSE), and accelerator-driven BD (Cedars-Sinai Accelerator+, CASSINI). Customer segments targeted are pharmaceutical and biotech companies, academic and government research institutions (LCSB, LIH, Notre Dame, ESA, NASA-aligned agencies), and advanced healthcare systems such as Cedars-Sinai. Operations span a Luxembourg headquarters in the House of BioHealth incubator and a US regional office in Los Angeles, with first orbital missions planned for 2026-2027 aboard the ISS (via Voyager) and Vast's Haven-1.

Short descriptiontext

Exobiosphere is a Luxembourg-based contract research organization founded in 2024 that operates the Orbital High-Throughput Screener to run automated drug discovery and disease modeling experiments in microgravity for pharmaceutical, biotech, academic and government customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEsch-sur-alzette, Luxembourg
HQ citystring
Esch-sur-alzette
HQ countrystring
Luxembourg
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, space-based drug discovery, high-throughput screening, microgravity biotechnology, pharmaceutical research platforms
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Contract Research Services (Space Biotechnology)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Research Services
TypeManaged Services
Description

Exobiosphere operates as the world's first contract research organization (CRO) dedicated to drug discovery in space. Revenue is generated through mission management contracts, research service fees, and per-mission pricing for pharmaceutical and biotech partners accessing the OHTS platform for drug screening and disease modeling.

exobiosphere.com
2Space Mission Integration Services
TypeProfessional Services
Description

Revenue from providing end-to-end microgravity research services including hardware qualification, mission preparation, execution of automated experiments in orbit, and delivery of scientific data to research teams on Earth. ESA contract covers science selection through mission execution.

exobiosphere.com
3Ground-based Platform Sales
TypeHardware Sales
Description

Sale and deployment of terrestrial versions of the automated high-throughput screening system to research institutions (e.g., University of Notre Dame) for biomedical research and ground-based testbed supporting future spaceflight experiments.

exobiosphere.com
4Data and Analytics Services
TypeData Monetisation
Description

Generation and sale of space-derived biological data to pharmaceutical and biotech partners for AI-driven drug discovery models, with real-time data transfer capabilities and post-flight molecular and functional analyses.

exobiosphere.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Mission-based research services
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies by mission scope, number of experiments (2,000+ per mission), platform utilization, and whether it includes pre-launch activities, mission execution, and post-mission data analysis. Custom quotes provided to pharma/biotech partners.

exobiosphere.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Exobiosphere operates as the world's first contract research organization (CRO) dedicated to drug discovery in space. The company develops and operates the Orbital High-Throughput Screener (OHTS), a compact, autonomous platform that runs 2,000+ simultaneous biological experiments per mission in microgravity. It sells mission-based research services, hardware platforms (orbital and ground-based versions), and derived biological data to pharmaceutical companies, biotech firms, and research institutions for drug screening, disease modeling, and target identification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 2,000+ simultaneous drug screening samples per mission
+3 more records
Product overview1 text field

Exobiosphere operates as a biotechnology company developing autonomous high-throughput screening platforms for life sciences research in microgravity. The company's portfolio centers on the Orbital High-Throughput Screener (OHTS) system—a miniaturized, self-contained automated laboratory platform that enables complex biological experimentation in space environments. The OHTS platform integrates precision liquid handling, environmental control, robotic manipulation, and live imaging to conduct thousands of simultaneous experiments per mission. The company offers end-to-end mission services covering feasibility assessment, assay adaptation, optimization and automation, mission preparation and launch, HTS execution with real-time monitoring, and post-mission data analysis and delivery. Exobiosphere's mission is to improve and extend health on Earth and in Space by leveraging microgravity conditions that accelerate cellular aging and disease progression, enabling more precise disease models and faster drug screening than achievable on Earth.

Product and service5 records
1Orbital High-Throughput Screener (OHTS)
CategoryCore product (space-qualified hardware platform)
Description

Compact, autonomous, miniaturized laboratory platform capable of conducting 2,000+ automated experiments per mission in microgravity. Integrates precision liquid handling (MANTIS from Formulatrix), environmental control, robotic manipulation, and live imaging (brightfield and fluorescent microscopy) in a carry-on-sized unit. Supports industry-standard 384- and 1536-well plates, with real-time experimental monitoring and data transfer to Earth. Designed for installation aboard the ISS and Vast's Haven-1 commercial space station for use by pharmaceutical and biotech research customers.

2Space-Based Contract Research Services
CategoryContract research services (CRO)
Description

End-to-end contract research services for drug discovery in space, covering feasibility assessment, assay adaptation, optimization and automation, mission preparation, launch, automated experiment execution on the OHTS platform, and post-mission data delivery. Sold to pharmaceutical companies, biotech firms, and research institutions on a per-mission basis.

3Ground-Based High-Throughput Screening Platform
CategoryHardware product (ground-based laboratory equipment)
Description

Terrestrial version of the automated OHTS platform sold to academic and research institutions for biomedical research and as a ground-based testbed supporting future spaceflight experiments. Operated by research labs such as Dr. Meenal Datta's lab at the University of Notre Dame for immunology and tumor microenvironment research.

4Space Mission Integration Services
CategoryProfessional mission services
Description

Professional services covering hardware qualification, mission preparation, execution of automated experiments in orbit, and delivery of scientific data to research teams on Earth. Includes full mission management and integration with space station operators (Vast, Voyager Technologies, Space Cargo Unlimited) and government customers such as ESA.

5Space-Derived Biological Data and Analytics Services
CategoryData and analytics services
Description

Generation, processing, and sale of space-derived biological data to pharmaceutical and biotech partners for AI-driven drug discovery models. Includes real-time data transfer from orbit, post-flight molecular and functional analyses, multi-OMICS readouts, high-content imaging, and FAIR (Findable, Accessible, Interoperable, Reusable) datasets.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierSupportTypeOthersAnnounced on2026-05-19
Description

Selected for seventh edition of Europe's largest space startup accelerator. Six-month program (May-October 2026) providing business coaching, mentoring, investor matchmaking, Demo Day access, international business trip, and €75,000 equity-free voucher.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-13
Description

Mission management contract for ISS operations - Voyager Technologies Europe serves as mission integrator for OHTS platform aboard ISS. Provides project management, NASA safety verification, integration, and on-orbit operations coordination for the permanently installed payload.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

€200K contract under Bioengineering in Space Environment challenge for nine-month feasibility study. Selected for end-to-end microgravity research service contract to operate OHTS on Vast's Haven-1, with science selection through ESA's Open Space Innovation Platform.

4Luxembourg Centre for Systems Biomedicine (LCSB)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

€1.4M Gravity-AI collaborative project funded under FNR AI-HPC BRIDGES Call 2025. Project develops microgravity-enabled AI predictive models for neurodegeneration (Parkinson's, Alzheimer's) combining space biology with high-performance computing and machine learning.

exobiosphere.com
5Luxembourg Centre for Systems Biomedicine (LCSB) - OH(T)SIZON
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-02-12
Description

OH(T)SIZON research project with FNR Industrial Fellowship to Dr. Beatriz Silva. Project optimizes end-to-end screening workflow for neuroinflammation drug discovery using Exobiosphere's OHTS platform configured with human monocyte reporter system.

exobiosphere.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

ESA BSGN joint project 'myrSpaceCardio' - pioneering initiative to develop next-generation human cardiac tissue models in microgravity. Exobiosphere provides OHTS platform for automated, standardized, high-throughput cardiac tissue testing in orbit.

7KIST-Europe Forschungsgesellschaft mbH
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

Non-profit research organization contributing scientific expertise in human stem-cell-derived organoids, phenotypic characterization, and multi-omics analysis for ESA BSGN myrSpaceCardio project.

exobiosphere.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-12-05
Description

Strategic agreement for acquisition and deployment of terrestrial version of automated high-throughput screening system. Platform to be installed at Notre Dame in mid-2026 for biomedical research and ground-based testbed supporting future spaceflight experiments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Academic medical center partnering with Exobiosphere to launch biomedical research aboard Vast's Haven-1 space station. Investigators will study organoid growth in microgravity to understand disease mechanisms and develop therapies for conditions affecting astronauts and Earth-based patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Signed MoU to jointly advance biomedical research and drug discovery in space. Partnership focuses on developing space-grade patient-derived models and validating therapeutic discovery pipelines for neurodegenerative diseases including Parkinson's through NCER-PD program.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-07-17
Description

MoU to enable high-frequency sample return from space. Exobiosphere's OHTS to be integrated into ElevationSpace's free-flying demonstrator satellite (ELS-R) and high-frequency recovery capsule (ELS-RS) for monthly sample return opportunities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-26
Description

Technology partnership for MANTIS Liquid Dispenser integration. Formulatrix's dispenser validated to work in microgravity - first high-throughput fluidic system validated in weightlessness. Critical enabler of precise liquid handling across Exobiosphere's mission roadmap.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

MoU signed at Paris Air Show to launch joint space missions deploying OHTS platform aboard Space Cargo Unlimited's BentoBox platform. First joint mission targeted for 2026, creating Europe's first fully integrated bio-research mission architecture with autonomous return capability.

14Vast
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-09
Description

Official payload partner for Haven-1 Lab - OHTS platform to be installed aboard world's first commercial crewed space station. Partnership enables automated cell culture experiments in microgravity for pharmaceutical and biotech partners.

exobiosphere.com
15EYnovation Program
Strategic tierSupportTypeOthersAnnounced on2025-03-10
Description

EY's startup acceleration program providing strategic business advisory, access to extensive network, and tailored growth acceleration services for space-based biotech commercialization.

exobiosphere.com
Strategic tierCoreTypeOthersAnnounced on2024-10-31
Description

Accepted into BioIncubator providing specialized laboratory spaces, advanced imaging systems, bioinformatics tools, and robotics essential for high-throughput screening in microgravity environments.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight9 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Kentucky-based commercial space company providing microgravity research platforms and payload services to pharma/biotech customers. Directly competes with Exobiosphere for the same CRO-style customers seeking automated on-orbit biological experimentation.

TypeDirect peer
Description

German microgravity biotech providing end-to-end research services and biotech experiment infrastructure in space, including cell biology and 3D tissue culture. Operates as a Europe-headquartered space CRO closely comparable to Exobiosphere's positioning.

TypeDirect peer
Description

Israel-based microgravity biotech operating miniaturized, remotely controlled orbital labs for pharmaceutical and biological research. Overlapping offering of automated on-orbit experimentation targeted at pharma and academic customers.

TypeBroad incumbent
Description

Established space infrastructure company with a portfolio of in-space biotech R&D platforms (e.g., SABL, BioFabrication Facility) used on ISS. A much larger incumbent whose biotech payload suite broadly overlaps with Exobiosphere's screening-as-a-service ambitions.

TypeEmerging player
Description

Early-stage company developing bioreactor and cell-culture systems for microgravity research. Emerging player intersecting Exobiosphere's territory in space-enabled tissue engineering and life sciences experimentation.

TypeEmerging player
Description

US in-space manufacturing company building orbital factories with reentry capsules. While its primary focus is materials (e.g., pharmaceuticals in microgravity), it is a complementary emerging player that could overlap or partner with Exobiosphere on sample-return missions.

TypeEmerging player
Description

University of Colorado-based research center offering end-to-end microgravity life sciences payload services with long ISS flight heritage. Provides research-as-a-service in a similar CRO style for academic and pharma customers.

TypeOthers
Description

ISS mission-management integrator and space-tech prime that serves as Exobiosphere's mission integrator. Adjacent ecosystem participant rather than direct competitor; valuations/route-to-market partner for orbital deployments.

TypeEmerging player
Description

Microgravity-enabled biotech developing protein-based retinal implants manufactured on the ISS. Leverages microgravity manufacturing similar to Exobiosphere's biomedical use cases but focused on a single therapeutic product rather than a CRO platform.

TypeOthers
Description

Commercial space station developer building Haven-1 and successor stations. Strategic host/customer of Exobiosphere's OHTS platform rather than a competitor, but a critical dependency for orbital revenue.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exobiosphere

Contract Research Services (Space Biotechnology)exobiosphere.com

Exobiosphere is a Luxembourg-based contract research organization founded in 2024 that operates the Orbital High-Throughput Screener to run automated drug discovery and disease modeling experiments in microgravity for pharmaceutical, biotech, academic and government customers.

What Exobiosphere does

Exobiosphere SARL is a Luxembourg-headquartered biotechnology company founded in 2024 that operates the world's first contract research organization (CRO) dedicated to high-throughput drug discovery in space. The company built and commercializes the Orbital High-Throughput Screener (OHTS), a carry-on suitcase-sized autonomous laboratory that integrates precision nanoliter liquid handling (via an integrated Formulatrix MANTIS dispenser), environmental control, robotic manipulation, and brightfield and fluorescent microscopy to run 2,000+ simultaneous biological experiments per microgravity mission. End-to-end mission services span assay adaptation, hardware qualification, launch integration, automated in-orbit experimentation with real-time data downlink, and post-mission data analysis for pharmaceutical, biotech, academic and government customers.

The business model is project- and mission-based with custom quotes; disclosed revenue streams include contract research services (per-mission CRO fees for pharma/biotech), space mission integration services (end-to-end orbital research as exemplified by the ESA contract), ground-based platform sales (terrestrial OHTS units sold to institutions such as the University of Notre Dame) and emerging data and analytics monetization tied to space-derived biological datasets. Go-to-market is direct enterprise sales augmented by channel partnerships with commercial space station operators (Vast, Voyager Technologies, Space Cargo Unlimited, ElevationSpace), government procurement (ESA, Luxembourg Space Agency, LuxIMPULSE), and accelerator-driven BD (Cedars-Sinai Accelerator+, CASSINI). Customer segments targeted are pharmaceutical and biotech companies, academic and government research institutions (LCSB, LIH, Notre Dame, ESA, NASA-aligned agencies), and advanced healthcare systems such as Cedars-Sinai. Operations span a Luxembourg headquarters in the House of BioHealth incubator and a US regional office in Los Angeles, with first orbital missions planned for 2026-2027 aboard the ISS (via Voyager) and Vast's Haven-1.

Exobiosphere firmographics

Firmographics
Name
Exobiosphere
Legal name
Exobiosphere SARL
Website
https://exobiosphere.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Exobiosphere is a Luxembourg-based contract research organization founded in 2024 that operates the Orbital High-Throughput Screener to run automated drug discovery and disease modeling experiments in microgravity for pharmaceutical, biotech, academic and government customers.
Ownership category
akta.pro rank

Exobiosphere industry classification

Industry
Product category
Contract Research Services (Space Biotechnology)
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Contract research services
  • Space-based drug discovery
  • High-throughput screening
  • Microgravity biotechnology
  • Pharmaceutical research platforms

Where Exobiosphere is headquartered

Location

Headquarters

HQ city
Esch-sur-alzette
HQ country
Luxembourg
HQ region
Europe

Offices2 records

Markets served

Exobiosphere business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Contract Research Services: Exobiosphere operates as the world's first contract research organization (CRO) dedicated to drug discovery in space. Revenue is generated through mission management contracts, research service fees, and per-mission pricing for pharmaceutical and biotech partners accessing the OHTS platform for drug screening and disease modeling.
  2. Space Mission Integration Services: Revenue from providing end-to-end microgravity research services including hardware qualification, mission preparation, execution of automated experiments in orbit, and delivery of scientific data to research teams on Earth. ESA contract covers science selection through mission execution.
  3. Ground-based Platform Sales: Sale and deployment of terrestrial versions of the automated high-throughput screening system to research institutions (e.g., University of Notre Dame) for biomedical research and ground-based testbed supporting future spaceflight experiments.
  4. Data and Analytics Services: Generation and sale of space-derived biological data to pharmaceutical and biotech partners for AI-driven drug discovery models, with real-time data transfer capabilities and post-flight molecular and functional analyses.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMission-based research services

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Exobiosphere product offering

Product offering

Core offering

Exobiosphere operates as the world's first contract research organization (CRO) dedicated to drug discovery in space. The company develops and operates the Orbital High-Throughput Screener (OHTS), a compact, autonomous platform that runs 2,000+ simultaneous biological experiments per mission in microgravity. It sells mission-based research services, hardware platforms (orbital and ground-based versions), and derived biological data to pharmaceutical companies, biotech firms, and research institutions for drug screening, disease modeling, and target identification.

Product overview

Exobiosphere operates as a biotechnology company developing autonomous high-throughput screening platforms for life sciences research in microgravity. The company's portfolio centers on the Orbital High-Throughput Screener (OHTS) system—a miniaturized, self-contained automated laboratory platform that enables complex biological experimentation in space environments. The OHTS platform integrates precision liquid handling, environmental control, robotic manipulation, and live imaging to conduct thousands of simultaneous experiments per mission. The company offers end-to-end mission services covering feasibility assessment, assay adaptation, optimization and automation, mission preparation and launch, HTS execution with real-time monitoring, and post-mission data analysis and delivery. Exobiosphere's mission is to improve and extend health on Earth and in Space by leveraging microgravity conditions that accelerate cellular aging and disease progression, enabling more precise disease models and faster drug screening than achievable on Earth.

Differentiator

Problem solved

Functional benefit

Products and services

  • Orbital High-Throughput Screener (OHTS) Compact, autonomous, miniaturized laboratory platform capable of conducting 2,000+ automated experiments per mission in microgravity. Integrates precision liquid handling (MANTIS from Formulatrix), environmental control, robotic manipulation, and live imaging (brightfield and fluorescent microscopy) in a carry-on-sized unit. Supports industry-standard 384- and 1536-well plates, with real-time experimental monitoring and data transfer to Earth. Designed for installation aboard the ISS and Vast's Haven-1 commercial space station for use by pharmaceutical and biotech research customers.
  • Space-Based Contract Research Services End-to-end contract research services for drug discovery in space, covering feasibility assessment, assay adaptation, optimization and automation, mission preparation, launch, automated experiment execution on the OHTS platform, and post-mission data delivery. Sold to pharmaceutical companies, biotech firms, and research institutions on a per-mission basis.
  • Ground-Based High-Throughput Screening Platform Terrestrial version of the automated OHTS platform sold to academic and research institutions for biomedical research and as a ground-based testbed supporting future spaceflight experiments. Operated by research labs such as Dr. Meenal Datta's lab at the University of Notre Dame for immunology and tumor microenvironment research.
  • Space Mission Integration Services Professional services covering hardware qualification, mission preparation, execution of automated experiments in orbit, and delivery of scientific data to research teams on Earth. Includes full mission management and integration with space station operators (Vast, Voyager Technologies, Space Cargo Unlimited) and government customers such as ESA.
  • Space-Derived Biological Data and Analytics Services Generation, processing, and sale of space-derived biological data to pharmaceutical and biotech partners for AI-driven drug discovery models. Includes real-time data transfer from orbit, post-flight molecular and functional analyses, multi-OMICS readouts, high-content imaging, and FAIR (Findable, Accessible, Interoperable, Reusable) datasets.

Quantifiable outcome

  • 2,000+ simultaneous drug screening samples per mission
  • +3 more outcomes

Companies that use Exobiosphere

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Exobiosphere technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature4 records

Exobiosphere partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered support, core, strategic and minor.

  • CASSINI Business AcceleratorsupportOthers · 19 May 2026Selected for seventh edition of Europe's largest space startup accelerator. Six-month program (May-October 2026) providing business coaching, mentoring, investor matchmaking, Demo Day access, international business trip, and €75,000 equity-free voucher.
  • Voyager TechnologiescoreTechnology or Integration · 13 May 2026Mission management contract for ISS operations - Voyager Technologies Europe serves as mission integrator for OHTS platform aboard ISS. Provides project management, NASA safety verification, integration, and on-orbit operations coordination for the permanently installed payload.
  • European Space Agency (ESA)coreStrategic or Co-development Partner · 7 April 2026€200K contract under Bioengineering in Space Environment challenge for nine-month feasibility study. Selected for end-to-end microgravity research service contract to operate OHTS on Vast's Haven-1, with science selection through ESA's Open Space Innovation Platform.
  • Luxembourg Centre for Systems Biomedicine (LCSB)coreStrategic or Co-development Partner · 18 February 2026€1.4M Gravity-AI collaborative project funded under FNR AI-HPC BRIDGES Call 2025. Project develops microgravity-enabled AI predictive models for neurodegeneration (Parkinson's, Alzheimer's) combining space biology with high-performance computing and machine learning.
  • Luxembourg Centre for Systems Biomedicine (LCSB) - OH(T)SIZONstrategicStrategic or Co-development Partner · 12 February 2026OH(T)SIZON research project with FNR Industrial Fellowship to Dr. Beatriz Silva. Project optimizes end-to-end screening workflow for neuroinflammation drug discovery using Exobiosphere's OHTS platform configured with human monocyte reporter system.
  • Myriamed GmbHstrategicStrategic or Co-development Partner · 3 February 2026ESA BSGN joint project 'myrSpaceCardio' - pioneering initiative to develop next-generation human cardiac tissue models in microgravity. Exobiosphere provides OHTS platform for automated, standardized, high-throughput cardiac tissue testing in orbit.
  • KIST-Europe Forschungsgesellschaft mbHminorStrategic or Co-development Partner · 3 February 2026Non-profit research organization contributing scientific expertise in human stem-cell-derived organoids, phenotypic characterization, and multi-omics analysis for ESA BSGN myrSpaceCardio project.
  • University of Notre DamestrategicStrategic or Co-development Partner · 5 December 2025Strategic agreement for acquisition and deployment of terrestrial version of automated high-throughput screening system. Platform to be installed at Notre Dame in mid-2026 for biomedical research and ground-based testbed supporting future spaceflight experiments.
  • Cedars-SinaicoreStrategic or Co-development Partner · 1 December 2025Academic medical center partnering with Exobiosphere to launch biomedical research aboard Vast's Haven-1 space station. Investigators will study organoid growth in microgravity to understand disease mechanisms and develop therapies for conditions affecting astronauts and Earth-based patients.
  • Luxembourg Institute of Health (LIH)coreStrategic or Co-development Partner · 18 November 2025Signed MoU to jointly advance biomedical research and drug discovery in space. Partnership focuses on developing space-grade patient-derived models and validating therapeutic discovery pipelines for neurodegenerative diseases including Parkinson's through NCER-PD program.
  • ElevationSpacestrategicStrategic or Co-development Partner · 17 July 2025MoU to enable high-frequency sample return from space. Exobiosphere's OHTS to be integrated into ElevationSpace's free-flying demonstrator satellite (ELS-R) and high-frequency recovery capsule (ELS-RS) for monthly sample return opportunities.
  • FormulatrixcoreTechnology or Integration · 26 June 2025Technology partnership for MANTIS Liquid Dispenser integration. Formulatrix's dispenser validated to work in microgravity - first high-throughput fluidic system validated in weightlessness. Critical enabler of precise liquid handling across Exobiosphere's mission roadmap.
  • Space Cargo UnlimitedcoreStrategic or Co-development Partner · 17 June 2025MoU signed at Paris Air Show to launch joint space missions deploying OHTS platform aboard Space Cargo Unlimited's BentoBox platform. First joint mission targeted for 2026, creating Europe's first fully integrated bio-research mission architecture with autonomous return capability.
  • VastcoreStrategic or Co-development Partner · 9 April 2025Official payload partner for Haven-1 Lab - OHTS platform to be installed aboard world's first commercial crewed space station. Partnership enables automated cell culture experiments in microgravity for pharmaceutical and biotech partners.
  • EYnovation ProgramsupportOthers · 10 March 2025EY's startup acceleration program providing strategic business advisory, access to extensive network, and tailored growth acceleration services for space-based biotech commercialization.
  • House of BioHealthcoreOthers · 31 October 2024Accepted into BioIncubator providing specialized laboratory spaces, advanced imaging systems, bioinformatics tools, and robotics essential for high-throughput screening in microgravity environments.

Scale indicators5 records

Recent moves6 records

Expansion highlights9 records

Exobiosphere competitors and assessment

Company assessment

Direct peers

  • Space Tango: Kentucky-based commercial space company providing microgravity research platforms and payload services to pharma/biotech customers. Directly competes with Exobiosphere for the same CRO-style customers seeking automated on-orbit biological experimentation.
  • Yuri (formerly Yuri Gravity): German microgravity biotech providing end-to-end research services and biotech experiment infrastructure in space, including cell biology and 3D tissue culture. Operates as a Europe-headquartered space CRO closely comparable to Exobiosphere's positioning.
  • SpacePharma: Israel-based microgravity biotech operating miniaturized, remotely controlled orbital labs for pharmaceutical and biological research. Overlapping offering of automated on-orbit experimentation targeted at pharma and academic customers.

Broad incumbents

  • Redwire Corporation: Established space infrastructure company with a portfolio of in-space biotech R&D platforms (e.g., SABL, BioFabrication Facility) used on ISS. A much larger incumbent whose biotech payload suite broadly overlaps with Exobiosphere's screening-as-a-service ambitions.

Emerging players

  • Prometheus Life Technologies: Early-stage company developing bioreactor and cell-culture systems for microgravity research. Emerging player intersecting Exobiosphere's territory in space-enabled tissue engineering and life sciences experimentation.
  • Varda Space Industries: US in-space manufacturing company building orbital factories with reentry capsules. While its primary focus is materials (e.g., pharmaceuticals in microgravity), it is a complementary emerging player that could overlap or partner with Exobiosphere on sample-return missions.
  • BioServe Space Technologies: University of Colorado-based research center offering end-to-end microgravity life sciences payload services with long ISS flight heritage. Provides research-as-a-service in a similar CRO style for academic and pharma customers.
  • LambdaVision: Microgravity-enabled biotech developing protein-based retinal implants manufactured on the ISS. Leverages microgravity manufacturing similar to Exobiosphere's biomedical use cases but focused on a single therapeutic product rather than a CRO platform.

Others

  • Voyager Technologies: ISS mission-management integrator and space-tech prime that serves as Exobiosphere's mission integrator. Adjacent ecosystem participant rather than direct competitor; valuations/route-to-market partner for orbital deployments.
  • Vast: Commercial space station developer building Haven-1 and successor stations. Strategic host/customer of Exobiosphere's OHTS platform rather than a competitor, but a critical dependency for orbital revenue.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Exobiosphere social profiles

Digital presence

Exobiosphere financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exobiosphere leadership team

Management profile

Number of profiles

Profiles4 records

Exobiosphere funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exobiosphere M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exobiosphere

What does Exobiosphere do?

Exobiosphere operates as the world's first contract research organization (CRO) dedicated to drug discovery in space. The company develops and operates the Orbital High-Throughput Screener (OHTS), a compact, autonomous platform that runs 2,000+ simultaneous biological experiments per mission in microgravity. It sells mission-based research services, hardware platforms (orbital and ground-based versions), and derived biological data to pharmaceutical companies, biotech firms, and research institutions for drug screening, disease modeling, and target identification.

Is Exobiosphere a public or private company?

Exobiosphere is a private company. It is classified as venture growth investor backed and is currently operating.

When was Exobiosphere founded?

Exobiosphere was founded in 2024. It employs 11 to 50 people.

Where is Exobiosphere based?

Exobiosphere is headquartered in Esch-sur-alzette, Luxembourg, in the Europe region.

How does Exobiosphere make money?

Four revenue lines are on record. Contract Research Services are the primary driver. The others are space Mission Integration Services, ground-based Platform Sales and data and Analytics Services.

Who are Exobiosphere's main competitors?

Direct peers on record are Space Tango, Yuri (formerly Yuri Gravity) and SpacePharma. Redwire Corporation is listed as a broad incumbent. Emerging players are Prometheus Life Technologies, Varda Space Industries, BioServe Space Technologies and LambdaVision. Others are Voyager Technologies and Vast.

Does Exobiosphere have an API?

No public API is recorded for Exobiosphere.

What industry is Exobiosphere in?

Exobiosphere's product category is Contract Research Services (Space Biotechnology). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Interesting EngineeringUS space factory secures 1st microgravity drug research bookingExobiosphere's automated drug laboratory OHTS secured a place on Outpost's Space Factories platform, becoming the first commercial customer. The module will fly aboard CarryAll spacecraft ahead of a 2028 mission, with sample return to Earth. The companies aim to combine microgravity access with repeatable returns to shorten experimental cycles.PR NewswireExobiosphere to Become the First Commercial Customer of Outpost's New Space Factories, Bringing Microgravity Drug Discovery to Orbit and BackExobiosphere will fly its Orbital High-Throughput System as the first customer module on Outpost's Space Factories platform, using CarryAll spacecraft. The agreement enables repeatable microgravity drug discovery with reliable Earth return, ahead of Outpost's 2028 orbital mission.American City Business JournalsExobiosphere inks UTHealth Houston, Voyager space research dealsExobiosphere signed agreements with UTHealth Houston and Nanoracks for space research missions. The biotech company also opened a local office, following a trend of Houston academic institutions partnering with commercial entities to bring research to low Earth orbit.SiftedFrom space-based healthcare to sustainable materials: Meet MSISV’s 2026 EMEA cohortMorgan Stanley's MSISV accelerator launched its 2026 EMEA cohort, featuring startups and non-profits across space healthcare, sustainable materials, and community impact. The cohort spans four thematic categories: Environment, Health & Wellbeing, Economic Empowerment, and Education & Human Capital, with companies like Exobiosphere and Abalobi highlighted.American City Business JournalsExobiosphere inks UTHealth Houston, Voyager space research dealsExobiosphere inked agreements with UTHealth Houston and Nanoracks for space research missions. The biotech company also opened a local office, following a trend of Houston academic institutions partnering with commercial entities to bring research to low Earth orbit.GurufocusCommercial Demand for Microgravity Drug Discovery Accelerates asVoyager Technologies and Exobiosphere announced two additional ISS research campaigns, with Exobiosphere's OHTS platform scheduled for installation in April 2027. The campaigns follow in June and August–September 2027, turning microgravity drug discovery into a recurring service. Voyager Europe will manage missions under the existing master agreement.Tech.euEuropean tech weekly recap: Over €763M invested across 35+ dealsEuropean tech funding last week totaled over €763 million across more than 35 deals and 10 exits. Software raised the most at €355.3 million, with the UK leading at €393.5 million. Notable rounds included Lovable's $400 million raise and Cambridge Aerospace's $300 million.SiliconluxembourgExobiosphere Secures €1M JEI BoostExobiosphere, a Luxembourg space biotech startup, secured €1 million in non-dilutive funding through the JEI aid scheme. The grant will support commercial expansion, team growth, and scaling its orbital drug-discovery platform. The scheme co-finances up to 70% of financing needs, capped at €1M.CapitalСтартъп новини | Лекарства от Космоса; Електрически хеликоптер; Сделка за 10 млрд. долараExobiosphere, a Luxembourg-based startup, received €1 million in non-dilutive funding to develop an orbital platform for biotech research, enabling over 2,000 automated experiments per mission. Anthropic signed a €10 billion deal with Volta Infra Holdings to use a Bitdeer data center in Norway, equipped with Nvidia Vera Rubin chips, to diversify its hardware capacity ahead of its IPO.StartbaseExobiosphere erhält eine Million Euro staatliche Förderung für Space-Biotech-PlattformLuxembourg-based space biotech company Exobiosphere secured one million euros in non-dilutive funding from the Luxembourg government's Jeune Entreprise Innovante (JEI) program. The funds will be used to scale its automated biomedicine platform for microgravity research and expand its commercial operations internationally. This support follows recent milestones including an ESA contract and a $1 million investment, marking a shift toward market expansion.